Freenome (FRNM) investor relations material

Company overview and business model

• Focuses on early cancer detection through blood-based, multiomics tests leveraging AI/ML for multi-cancer and multi-disease screening.

• Proprietary platform integrates DNA, RNA, protein, and other analytes with advanced automation and clinical trials.

• Commercialization strategy includes partnerships with Exact Sciences (U.S. CRC commercialization) and Roche (ex-U.S. multi-cancer kits).

• Initial product, SimpleScreen CRC, received FDA approval for colorectal cancer screening in adults 45+ at average risk.

• Pipeline includes lung cancer and multi-cancer early detection (PCD/MCED) tests, with ongoing clinical studies and future LDT/IVD launches planned.

Financial performance and metrics

• Net losses: $132.6M for six months ended June 30, 2026; $219.3M for year ended December 31, 2025; accumulated deficit of $1.5B as of June 30, 2026.

• Revenue for six months ended June 30, 2026: $6.5M, primarily from license/collaboration agreements and limited product/service sales.

• Cash, cash equivalents, and short-term marketable securities: $102M as of June 30, 2026.

• Gross proceeds from PIPE and business combination: $310.7M; net proceeds after costs: $295.5M.

• Projected to be funded through 2028 with current resources and expected milestone payments.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling securityholders, except for up to $36.3M if options and warrants are exercised for cash.

• Any proceeds from option/warrant exercises will be used for general corporate purposes and working capital.

• Significant investments planned for R&D, commercialization, regulatory approvals, and expansion of infrastructure.